Health

Virtual twin to improve treatment with cancer immunotherapies

COLOGNE, Germany, Dec. 13, 2023 /PRNewswire/ -- An international team started the research project CERTAINTY inDecember 2023. Together with partners from science, industry and the healthcare sector, the project team led by the Fraunhofer Institute for Cell Therapy and Immunology IZI aims to devel...

2023-12-13 21:06 1357

Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announcedphase II proof-...

2023-12-13 21:00 1576

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins) (WU-KONG6) were published in the peer-...

2023-12-13 18:00 1600

Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or Intolerant CML-CP

SUZHOU, China and ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized...

2023-12-13 16:47 2364

WuXi Vaccines Wins Second Consecutive "Best Vaccine CMO Award" at AVEA 2023

SINGAPORE, Dec. 12, 2023  /PRNewswire/ -- WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), was named "Best Vaccine CMO of the Year" for the second consecutive year at the 2023 Asia-Pacific Vaccine Excellence Awards (AVEA) ceremony.  The AVEA 202...

2023-12-13 08:30 1478

CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting

SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2023 American Society of Hematology ("ASH") Annual Meetin...

2023-12-12 21:50 1573

KOSMODE HEALTH SINGAPORE PTE LTD, CLINCHES "THE MOST TRANSFORMATIONAL COLLABORATION" 2023 SICC AWARDS IN PARTNERSHIP WITH NESTLÉ SINGAPORE AND NESTLÉ R&D CENTRE.

Achieving functional food security that is good for health of the people and health of the earth SINGAPORE, Dec. 12, 2023 /PRNewswire/ -- KosmodeHealth Singapore , proudly announces its triumphant win of "The Most Transformational Collaboration" at the prestigious 202...

2023-12-12 20:00 1894

Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH

SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held inSan Diego, California from December 9-12. The data showcased updated results of Dizal's ...

2023-12-12 18:00 1522

WuXi Biologics Named to 2023 Dow Jones Sustainability World Index

* Identified as a global sustainability leader by S&P Global * Committed to generating long-term value for all stakeholders SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), an...

2023-12-12 17:00 2376

Fertility Journey with Femometer Ring: Where Style Meets Precision in Ovulation Tracking

PRINCETON, N.J., Dec. 12, 2023 /PRNewswire/ -- In a groundbreaking advancement within women's health technology, the Femometer Smart Ring has emerged as a trailblazer, reshaping the landscape of basal body temperature tracking, fertility awareness for conception and overall well-being. In May 20...

2023-12-12 14:26 1225

MGI Wraps Up Inaugural the Future of Omics Research Summit

DUBAI, UAE, Dec. 11, 2023 /PRNewswire/ -- MGI, a company committed to building core tools and technology to lead life science, recently concluded its inaugural The Future of Omics Research Summit, the global event focused on the field of population genomics, metagenomics research and precision me...

2023-12-12 11:09 1241

Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety

SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the results of lisaftoclax (A...

2023-12-12 09:41 2340

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 11, 2023 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", H...

2023-12-12 03:30 1510

Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project

* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therape...

2023-12-11 22:30 1674

Zhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer Treatments

SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin"),...

2023-12-11 21:00 2573

Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting

Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study SHANGHAI and SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. ("Yingli Pharma"), a biopharmaceutical company focused ...

2023-12-11 21:00 1466

HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors

WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to...

2023-12-11 20:00 1435

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial

SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the "A Randomized, Open-label, Controlled, Mu...

2023-12-11 20:00 1273

2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results

-     A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, MD, PhD, Academician of the Chinese Academy of Engineering -     70% of the patients enrolled in phase Ib study were previously treated with CDK4/6 inhibitors  -     Demonstrated a confirmed objecti...

2023-12-11 18:55 1328

Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib

SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study ...

2023-12-11 13:30 1322
1 ... 45464748495051 ... 273